{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:08Z","timestamp":1790239388174,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.ejca.2006.02.010","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T03:34:33Z","timestamp":1149651273000},"page":"1484-1490","source":"Crossref","is-referenced-by-count":70,"title":["Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma"],"prefix":"10.1016","volume":"42","author":[{"given":"F.","family":"Grosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dileo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stacchiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bertulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Piovesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D\u2019Incalci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2006.02.010_bib1","series-title":"Cancer: Principles and Practice of Oncology","first-page":"841","article-title":"Soft tissue sarcoma","author":"Brennan","year":"2001"},{"key":"10.1016\/j.ejca.2006.02.010_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(00)00016-4","article-title":"Management of soft-tissue sarcomas: an overview and update","volume":"1","author":"Singer","year":"2000","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib3","first-page":"572","article-title":"Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities","volume":"24","author":"Keohan","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib4","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1200\/JCO.1997.15.6.2378","article-title":"High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies\u2014Dose-response and schedule dependence","volume":"15","author":"Patel","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib5","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.1995.13.7.1600","article-title":"High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas","volume":"13","author":"Le Cesne","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0959-8049(99)00240-3","article-title":"Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group","volume":"36","author":"Nielsen","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2006.02.010_bib7","first-page":"13","article-title":"Chemotherapy of advanced sarcomas of bone and soft tissue","volume":"19","author":"Antman","year":"1992","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib8","first-page":"1969","article-title":"Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative","volume":"97","author":"Okuno","year":"2003","journal-title":"Oncology Group Cancer"},{"key":"10.1016\/j.ejca.2006.02.010_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0959-8049(01)00408-7","article-title":"Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group","volume":"38","author":"Svancarova","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2006.02.010_bib10","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P","article-title":"Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face","volume":"86","author":"Fata","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.02.010_bib11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3109\/07357909809011697","article-title":"Phase II trial of paclitaxel in patients with soft-tissue sarcoma","volume":"16","author":"Casper","year":"1998","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ejca.2006.02.010_bib12","first-page":"179","article-title":"Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA","volume":"14","author":"Bonfanti","year":"1999","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/j.ejca.2006.02.010_bib13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1023\/A:1008224322396","article-title":"In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients","volume":"9","author":"Izbicka","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib14","first-page":"2908","article-title":"Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent","volume":"7","author":"Li","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2006.02.010_bib15","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1517\/13543784.12.11.1843","article-title":"Preclinical and clinical results with the natural marine product ET-743","volume":"12","author":"D\u2019Incalci","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.ejca.2006.02.010_bib16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2001.19.5.1256","article-title":"Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors","volume":"19","author":"Taamma","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib17","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","article-title":"Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients","volume":"22","author":"Yovine","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib18","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2001.19.5.1248","article-title":"Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity","volume":"19","author":"Delaloge","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","article-title":"Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy","volume":"22","author":"Garcia-Carbonero","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0959-8049(01)80606-7","article-title":"Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24-h infusion schedule","volume":"37","author":"Le Cesne","year":"2001","journal-title":"Proc ECCO 11, Eur Journal of Cancer"},{"key":"10.1016\/j.ejca.2006.02.010_bib21","first-page":"187a","article-title":"Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743","volume":"19","author":"Gomez","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib22","first-page":"5902","article-title":"Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat","volume":"63","author":"Donald","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2006.02.010_bib23","first-page":"4256","article-title":"Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat","volume":"62","author":"Donald","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2006.02.010_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-003-0744-3","article-title":"Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro","volume":"53","author":"Donald","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2006.02.010_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-002-0498-3","article-title":"Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity","volume":"50","author":"Puchalski","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2006.02.010_bib26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","article-title":"Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial","volume":"23","author":"Le Cesne","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib27","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1200\/JCO.2005.09.032","article-title":"Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails","volume":"23","author":"Sessa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib28","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1200\/jco.2004.22.14_suppl.9000","article-title":"Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy","volume":"22","author":"Samuels","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2006.02.010_bib29","first-page":"7450","article-title":"Correlation between the pattern of DNA repair efficiency and the natural history of patients with advanced sarcoma treated with ET-743 (Yondelis)","volume":"15","author":"Van Oosterom","year":"2004","journal-title":"Proc Eu Soc Med Oncology"},{"key":"10.1016\/j.ejca.2006.02.010_bib30","doi-asserted-by":"crossref","unstructured":"Van Oosterom A, Maki R, Taron M, et al. Impact of the DNA repair efficiency in the outcome of sarcoma patients treated with ET-743 (Yondelis). Proc 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2004; abstr 479.","DOI":"10.1016\/S1359-6349(04)80487-7"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906002711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906002711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T06:15:36Z","timestamp":1555654536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804906002711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0959804906002711"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2006.02.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}